Quote this publication Share Print

JARDIANCE

DIABETOLOGY - New medicinal product
Opinions on drugs - Posted on Mar 04 2015

Reason for request

Inclusion

No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin

 

No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin

 

  • JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
  • The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.

Actual benefit

Modéré

Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate

Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate

Insuffisant

- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance


Improvement in actual benefit

V (absence)

In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.

In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable.

Sans objet